LifeStance (LFST) CTO logs PSU vesting; shares withheld to cover taxes

Rhea-AI Filing Summary

LifeStance Health Group, Inc. Chief Technology Officer Vukasin Paunovich reported equity compensation activity tied to performance-based restricted stock units. On March 9, 2026, he acquired 62,935 shares of common stock at $0.00 per share upon vesting of previously granted PSUs. On the same date, 18,541 shares were withheld at $6.91 per share to satisfy tax withholding obligations, which the company notes did not involve any open-market sale. Following these transactions, Paunovich directly holds 309,296 shares of common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Paunovich Vukasin

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	62,935	$0.00	--
Tax Withholding	Common Stock	18,541	$6.91	$128K

Holdings After Transaction: Common Stock — 327,837 shares (Direct)

Footnotes (1)

1. Represents performance-based restricted stock units ("PSUs") previously granted to the Reporting Person on June 11, 2025, which vested on March 9, 2026. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the net settlement of PSUs that vested on March 9, 2026. The shares withheld represent a reduction of shares issued to the Reporting Person upon settlement of vested PSUs and do not constitute any open-market sale.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paunovich Vukasin

(Last) (First) (Middle)

C/O LIFESTANCE HEALTH GROUP, INC.

4800 N. SCOTTSDALE ROAD, SUITE 2500

(Street)

SCOTTSDALE AZ 85251

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeStance Health Group, Inc. [ LFST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		A		62,935(1)	A	$0.00	327,837	D
Common Stock	03/09/2026		F(2)		18,541	D	$6.91	309,296	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents performance-based restricted stock units ("PSUs") previously granted to the Reporting Person on June 11, 2025, which vested on March 9, 2026.

2. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the net settlement of PSUs that vested on March 9, 2026. The shares withheld represent a reduction of shares issued to the Reporting Person upon settlement of vested PSUs and do not constitute any open-market sale.

	By: /s/ Ryan Pardo, Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did LifeStance Health (LFST) report for Vukasin Paunovich?

LifeStance Health reported that CTO Vukasin Paunovich received a grant settlement of 62,935 shares of common stock from vested performance-based restricted stock units. These PSUs were originally granted on June 11, 2025 and vested on March 9, 2026 as part of his compensation.

Were any LifeStance Health (LFST) shares sold on the open market in this Form 4?

No open-market sales occurred. The filing states 18,541 shares were withheld by the company solely to cover tax obligations from the PSU vesting. The footnote clarifies this withholding is a reduction in shares issued, not an open-market sale transaction.

How many LifeStance Health (LFST) shares does the CTO hold after this Form 4?

After the reported PSU vesting and tax withholding, CTO Vukasin Paunovich directly holds 309,296 shares of LifeStance Health common stock. This total reflects the net shares remaining following issuance of vested PSUs and the share withholding for associated tax liabilities.

What is the nature of the equity award reported for LifeStance Health (LFST) CTO?

The equity activity relates to performance-based restricted stock units (PSUs) previously granted on June 11, 2025. These PSUs vested on March 9, 2026, resulting in the issuance of common stock to the CTO as part of his long-term incentive compensation.

At what price were LifeStance Health (LFST) shares withheld for taxes in this filing?

The company withheld 18,541 shares at a price of $6.91 per share to satisfy tax withholding obligations from the PSU vesting. This withholding reduced the net shares delivered but did not involve any market sale of LifeStance Health stock.

Does this LifeStance Health (LFST) Form 4 indicate an options exercise by the CTO?

No stock options exercise is reported. The Form 4 describes settlement of performance-based restricted stock units into common shares and a related tax-withholding share reduction, rather than an exercise of stock options or other derivative securities.